Table 3.
suPAR and incident CKD stage 3 and ESRD in patients with ADPKD
| Variable | CKD Stage 3 | ESRD | ||
|---|---|---|---|---|
| HR, P Value | 95% CI | HR, P Value | 95% CI | |
| Model 0: suPAR (unadjusted) | ||||
| suPAR, per 100% increase (log2) | 3.11, <0.001 | 2.40 to 4.01 | 2.04, 0.02 | 1.15 to 3.60 |
| suPAR, <2.176 ng/ml (ref) | - | - | - | - |
| 2.176–2.826 ng/ml | 2.26, 0.01 | 1.20 to 4.24 | 2.01, 0.13 | 0.82 to 4.94 |
| ≥2.827 ng/ml | 4.26, <0.001 | 2.35 to 7.70 | 3.53, 0.003 | 1.52 to 8.20 |
| Model 1: suPAR+clinical characteristics | ||||
| suPAR, per 100% increase (log2) | 3.00, <0.001 | 1.91 to 4.74 | 2.21, 0.05 | 1.02 to 4.79 |
| suPAR, <2.176 ng/ml (ref) | - | - | - | - |
| 2.176–2.826 ng/ml | 1.94, 0.04 | 1.02 to 3.70 | 1.38, 0.51 | 0.53 to 3.58 |
| ≥2.827 ng/ml | 4.08, <0.001 | 2.19 to 7.61 | 3.94, 0.009 | 1.41 to 10.99 |
| Model 2: suPAR+clinical characteristics+eGFR | ||||
| suPAR, per 100% increase (log2) | 1.76, 0.02 | 1.11 to 2.81 | 1.90, 0.13 | 0.83 to 4.38 |
| suPAR, <2.176 ng/ml (ref) | - | - | - | - |
| 2.176–2.826 ng/ml | 1.76, 0.09 | 0.92 to 3.36 | 1.26, 0.64 | 0.48 to 3.30 |
| ≥2.827 ng/ml | 2.49, 0.005 | 1.31 to 4.71 | 3.63, 0.02 | 1.28 to 10.30 |
| Model 3: suPAR+clinical characteristics+eGFR+htTKV | ||||
| suPAR, per 100% increase (log2) | 1.69, 0.03 | 1.05 to 2.72 | 1.72, 0.14 | 0.83 to 3.68 |
| suPAR, <2.176 ng/ml (ref) | - | - | - | - |
| 2.176–2.826 ng/ml | 1.46, 0.27 | 0.75 to 2.84 | 1.27, 0.62 | 0.49 to 3.39 |
| ≥2.827 ng/ml | 2.18, 0.02 | 1.15 to 4.15 | 3.21, 0.03 | 1.13 to 9.09 |
| Interaction and subgroup analyses | P for Interaction | |||
| suPAR ≥2.827 ng/ml eGFRa | 0.89 | 0.72 | ||
| suPAR ≥2.827 ng/ml htTKV<600 ml/ma | 0.93 | 0.26 | ||
| suPAR ≥2.827 ng/ml genotypea | 0.99 | 0.99 | ||
The association between suPAR levels and CKD stage 3 was examined in a subset of both cohorts (n=546), whereas data on incident ESRD was only available in the CRISP cohort (n=180). Model 0 reports the association of suPAR both as a continuous and a categorical variable. Model 1 includes suPAR in addition to age, sex, body mass index, hypertension, use of ACEi/ARB and urine albumin-to-creatinine ratio. Models 2 and 3 and the interaction analyses include the clinical characteristics in model 1, in addition to the listed variables. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
Urine albumin-to-creatinine ratio was only available in the CRISP cohort.
Values in bold were statistically significant at P<0.05.